OlympicsGenentech
Jul 18, 2008
Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
In normal biological systems, HER2 functions as a co-receptor for a multitude of epidermal growth factor-like ligands that bind and activate other HER family members.
Comments
Please note by clicking on "Post Comment" you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.
| Topic | Updated | Last By | Comments |
|---|---|---|---|
| Genentech Rejects Roche Bid, For Now | Tue | CrossProfit | 2 |
| In brief: Volkswagen global sales up 5.8% | Jul 24 | El Paul | 1 |
| Genentech meets with Swiss firm | Jul 24 | Charles | 3 |
| Avastin Cancer Drug Linked To Anemia In Combo T... | Jul '08 | gdpawel | 1 |
| Five Indians in top 40 pharma global | May '08 | Xiangjun | 1 |
| SF Court Slashes $500 Million Settlement Agains... | Apr '08 | Icaro Sojo | 1 |
| Genentech severance set for some | Apr '08 | Do hire the ... | 6 |
Sagittarius
Most Popular